We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Evolus Inc (EOLS) USD0.00001

Sell:$11.48 Buy:$13.06 Change: $0.07 (0.60%)
NASDAQ:1.59%
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$11.48
Buy:$13.06
Change: $0.07 (0.60%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$11.48
Buy:$13.06
Change: $0.07 (0.60%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Contact details

Address:
520 Newport Center Dr Ste 1200
NEWPORT BEACH
92660-7022
United States
Telephone:
+1 (949) 2844555
Website:
https://www.evolus.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EOLS
ISIN:
US30052C1071
Market cap:
$707.65 million
Shares in issue:
61.37 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Moatazedi
    President, Chief Executive Officer, Director
  • Sandra Beaver
    Chief Financial Officer
  • Tomoko Yamagishi-Dressler
    Chief Marketing Officer
  • Nareg Sagherian
    Vice President, Head of Global Investor Relations and Corporate Communications
  • Rui Avelar
    Chief Medical Officer, Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.